Literature DB >> 30298281

Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma.

Fuyuhiko Motoi1, Yoshiaki Murakami2, Ken-Ichi Okada3, Ippei Matsumoto4, Kenichiro Uemura2, Sohei Satoi5, Masayuki Sho6, Goro Honda7, Takumi Fukumoto8, Hiroaki Yanagimoto5, Shoichi Kinoshita6, Masanao Kurata7, Shuichi Aoki9, Masamichi Mizuma9, Hiroki Yamaue3, Michiaki Unno9.   

Abstract

BACKGROUND: Survival after surgery for pancreatic adenocarcinoma (PA) is poor and heterogeneous, even for curative (R0) resection. Serum carbohydrate antigen (CA) 19-9 levels are important prognostic markers for resected PA. However, sustained elevation of CA19-9 in association with the patterns of recurrence has been rarely investigated.
METHODS: Patients who underwent R0 resection (n = 539) were grouped according to postoperative serum CA19-9 levels (Group E: sustained elevation; Group N: no elevation). Clinicopathological factors, patterns of recurrence, and survival were compared between the groups.
RESULTS: Group E (n = 159) had significantly shorter median overall survival (17.1 vs. 35.4 months, p < 0.0001) than Group N (n = 380). Postoperative CA19-9 elevation was a significant independent predictor of poor survival in multivariate analysis (hazard ratio 1.98, p < 0.0001). The rate of hepatic recurrence in Group E was 2.6-fold higher than in Group N (45% vs. 17%, p < 0.0001). Postoperative CA19-9 elevation was a strongest independent predictor of primary hepatic recurrence (p < 0.0001) by a multiple regression model. Loco-regional, peritoneal, and other distant recurrence did not differ between the groups. The extent of preoperative CA19-9 elevation was correlated sustained elevation of CA19-9 after surgery (p < 0.0001) and primary hepatic recurrence (p = 0.0019).
CONCLUSIONS: Sustained CA19-9 elevation was strong predictor of primary hepatic recurrence and short survival in cases of R0 resection for PA.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30298281     DOI: 10.1007/s00268-018-4814-4

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  7 in total

1.  Prognostic value of an inflammation-based nutritional score for patients with initially unresectable pancreatic adenocarcinoma undergoing conversion surgery following chemo-/radiotherapy.

Authors:  Takashi Kokumai; Shuichi Aoki; Masamichi Mizuma; Shimpei Maeda; Hideo Ohtsuka; Kei Nakagawa; Takanori Morikawa; Fuyuhiko Motoi; Takashi Kamei; Michiaki Unno
Journal:  Surg Today       Date:  2021-04-07       Impact factor: 2.549

2.  CA19-9 for detecting recurrence of pancreatic cancer.

Authors:  Azadeh Azizian; Felix Rühlmann; Tanja Krause; Markus Bernhardt; Peter Jo; Alexander König; Mathias Kleiß; Andreas Leha; Michael Ghadimi; Jochen Gaedcke
Journal:  Sci Rep       Date:  2020-01-28       Impact factor: 4.379

3.  Validation and modification of the AJCC 8th TNM staging system for pancreatic ductal adenocarcinoma in a Chinese cohort: A nationwide pancreas data center analysis.

Authors:  Hao Hu; Chang Qu; Bingjun Tang; Weikang Liu; Yongsu Ma; Yiran Chen; Xuehai Xie; Yan Zhuang; Hongqiao Gao; Xiaodong Tian; Yinmo Yang
Journal:  Chin J Cancer Res       Date:  2021-08-31       Impact factor: 5.087

4.  Prognostic Role of Carbohydrate Antigen 19 to 9 in Predicting Survival of Patients With Pancreatic Cancer: A Meta-Analysis.

Authors:  Yong-Ming Kang; Hao Wang; Ran Li; Gu Pan
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

5.  Overcoming acquired chemo-resistance to gemcitabine: implications from the perspective of multi-modal therapy including surgery for pancreatic cancer.

Authors:  Fuyuhiko Motoi
Journal:  Cancer Drug Resist       Date:  2021-09-07

6.  Heterogeneity of metabolic adaptive capacity affects the prognosis among pancreatic ductal adenocarcinomas.

Authors:  Taishu Kanda; Taiichi Wakiya; Keinosuke Ishido; Norihisa Kimura; Hiroaki Fujita; Tadashi Yoshizawa; Shintaro Goto; Yota Tatara; Hiroshi Kijima; Kenichi Hakamada
Journal:  J Gastroenterol       Date:  2022-07-03       Impact factor: 6.772

7.  Difference between carbohydrate antigen 19-9 and fluorine-18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma: Results of a dual-center study.

Authors:  Hirofumi Akita; Hidenori Takahashi; Hidetoshi Eguchi; Kei Asukai; Shinichiro Hasegawa; Hiroshi Wada; Yoshifumi Iwagami; Daisaku Yamada; Yoshito Tomimaru; Takehiro Noda; Kunihito Gotoh; Shogo Kobayashi; Yuichiro Doki; Masato Sakon
Journal:  Ann Gastroenterol Surg       Date:  2020-12-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.